4,4-diketo-beta-carotene, Beta,beta-carotene-4,4-dione, Cantaxantina, Cantaxantine, Canthaxanthine, Carophyll Red, CI Food Orange 8, Colour Index No. 40850, E161, Roxanthin Red 10.<br/><br/>


Overview Information

Canthaxanthin is a dye that is similar to the chemical that makes carrots orange. It occurs naturally and can also be made in a laboratory. People use it as medicine.

Canthaxanthin is used to reduce sensitivity to sunlight (photosensitivity) experienced by people who have a rare genetic disease called erythropoietic protoporphyria (EPP). In these people, sunlight can cause skin reactions such as rash, itch, and eczema. Canthaxanthin is also used to reduce sun sensitivity caused by certain medications. Some people also try it for relieving itching caused by sun exposure.

Orobronze (canthaxanthin) is sold in Canada as a nonprescription “tanning pill.” In the U.S., the Food and Drug Administration (FDA) has not approved tanning pills containing canthaxanthin. Nevertheless, these products seem to be readily available to people in the U.S. through mail order and tanning salons.

In foods, canthaxanthin is used as food coloring and is added to animal feed to improve the color of chicken skins, egg yolks, salmon, and trout.

In manufacturing, canthaxanthin is used in cosmetics and in medications.

How does it work?

Canthaxanthin is a dye similar to the carotenes in vegetables such as carrots. It deposits in the skin to produce an artificial “tan.” It might protect against sun sensitivity through antioxidant activity.


Uses & Effectiveness?

Possibly Effective for

  • An inherited blood disorder called erythropoietic protoporphyria (EPP). Taking canthaxanthin by mouth, with or without beta-carotene, seems to reduce rash, itching, or eczema caused by sensitivity to sunlight exposure in people with EPP.

Insufficient Evidence for

  • An autoimmune disorder called cutaneous lupus erythematosus (CLE). Early research suggests that taking canthaxanthin and beta-carotene by mouth improves symptoms following sunlight exposure in people with CLE.
  • A rash due to sun sensitivity (polymorphous light eruptions). Early research suggests that taking canthaxanthin and beta-carotene by mouth improves symptoms following sunlight exposure in people with polymorphous light eruptions.
  • Skin redness and irritation (psoriasis). Early research suggests that taking beta-carotene and canthaxanthin by mouth prior to and during phototherapy does not improve symptoms of psoriasis more than phototherapy alone.
  • A skin discoloration disorder (vitiligo). Early research suggests that taking a specific product (Carotinoid-N) containing canthaxanthin and beta-carotene improves the appearance of skin sores and protects against the sun in people with vitiligo. However, the treatment does not seem to affect skin pigmentation.
  • Sun sensitivity caused by certain medications.
  • Itching caused by the sun.
  • Artificial sun tanning.
  • Other conditions.
More evidence is needed to rate the effectiveness of canthaxanthin for these uses.

Side Effects

Side Effects & Safety

Canthaxanthin is LIKELY SAFE when taken by mouth in food amounts. However, it is LIKELY UNSAFE when taken by mouth in amounts needed for artificial tanning. Some people who have taken canthaxanthin for these purposes have experienced eye damage and vision loss.

At high doses, canthaxanthin has caused a serious, potentially fatal blood disorder called aplastic anemia. Canthaxanthin can also cause diarrhea, nausea, stomach cramps, dry and itchy skin, hives, orange or red body secretions, and other side effects.

Special Precautions & Warnings:

Pregnancy and breast-feeding: Canthaxanthin is POSSIBLY UNSAFE for pregnant or breast-feeding women when taken by mouth in medicinal amounts to reduce sun sensitivity. It’s LIKELY UNSAFE when taken by mouth in amounts needed to produce a tan. It can cause eye damage and other harmful effects.

Vitamin A allergy: People who are allergic to vitamin A and related chemicals called carotenoids might also be sensitive to canthaxanthin.



We currently have no information for CANTHAXANTHIN Interactions.



The following doses have been studied in scientific research:


  • For reducing and treating rash, itch, and/or eczema (symptoms of photosensitivity) in people with erythropoietic protoporphyria (EPP) when they are exposed to sunlight: 60 to 90 mg of canthaxanthin daily on average for three to five months per year.

View References


  • Acevedo, P. and Bertram, J. S. Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and beta-carotene in 10T1/2 cells. Carcinogenesis 1995;16(9):2215-2222. View abstract.
  • Arden, G. B., Oluwole, J. O., Polkinghorne, P., Bird, A. C., Barker, F. M., Norris, P. G., and Hawk, J. L. Monitoring of patients taking canthaxanthin and carotene: an electroretinographic and ophthalmological survey. Hum.Toxicol. 1989;8(6):439-450. View abstract.
  • Bareford, D., Cumberbatch, M., and Derrick, Tovey L. Plasma discolouration due to sun-tanning aids. Vox Sang. 1984;46(3):180-182. View abstract.
  • Bertram, J. S. and Bortkiewicz, H. Dietary carotenoids inhibit neoplastic transformation and modulate gene expression in mouse and human cells. Am J Clin.Nutr. 1995;62(6 Suppl):1327S-1336S. View abstract.
  • Bianchi, L., Tateo, F., Pizzala, R., Stivala, L. A., Grazia, Verri M., Melli, R., and Santamaria, L. Carotenoids reduce the chromosomal damage induced by bleomycin in human cultured lymphocytes. Anticancer Res 1993;13(4):1007-1010. View abstract.
  • Black, H. S. and Mathews-Roth, M. M. Protective role of butylated hydroxytoluene and certain carotenoids in photocarcinogenesis. Photochem.Photobiol. 1991;53(5):707-716. View abstract.
  • Bopp, S., el Hifnawi, E. L., and Laqua, H. [Canthaxanthin retinopathy and macular pucker]. J.Fr.Ophtalmol. 1989;12(12):891-896. View abstract.
  • Bruderer, P., Shahabpour, M., Christoffersen, S., Andre, J., and Ledoux, M. Hydroa vacciniforme treated by a combination of beta-carotene and canthaxanthin. Dermatology 1995;190(4):343-345. View abstract.
  • Carpenter, K. L., Hardwick, S. J., Albarani, V., and Mitchinson, M. J. Carotenoids inhibit DNA synthesis in human aortic smooth muscle cells. FEBS Lett. 3-19-1999;447(1):17-20. View abstract.
  • Carpenter, K. L., van, der, V, Hird, R., Dennis, I. F., Ding, T., and Mitchinson, M. J. The carotenoids beta-carotene, canthaxanthin and zeaxanthin inhibit macrophage-mediated LDL oxidation. FEBS Lett. 1-20-1997;401(2-3):262-266. View abstract.
  • Daicker, B., Schiedt, K., Adnet, J. J., and Bermond, P. Canthaxanthin retinopathy. An investigation by light and electron microscopy and physicochemical analysis. Graefes Arch.Clin.Exp.Ophthalmol. 1987;225(3):189-197. View abstract.
  • Daubrawa, F., Sies, H., and Stahl, W. Astaxanthin diminishes gap junctional intercellular communication in primary human fibroblasts. J Nutr 2005;135(11):2507-2511. View abstract.
  • De Laey, J. J. Flecked retina disorders. Bull.Soc Belge Ophtalmol. 1993;249:11-22. View abstract.
  • Di Mascio, P., Devasagayam, T. P., Kaiser, S., and Sies, H. Carotenoids, tocopherols and thiols as biological singlet molecular oxygen quenchers. Biochem Soc Trans 1990;18(6):1054-1056. View abstract.
  • Eales, L. The effects of canthaxanthin on the photocutaneous manifestations of porphyria. S.Afr.Med.J. 12-16-1978;54(25):1050-1052. View abstract.
  • ElAttar, T. M. and Lin, H. S. Effect of retinoids and carotenoids on prostaglandin formation by oral squamous carcinoma cells. Prostaglandins Leukot.Essent.Fatty Acids 1991;43(3):175-178. View abstract.
  • Gunson, H. H., Merry, A. H., Britton, G., and Stratton, F. Detection of carotenoids in blood donors taking Orobronze: a cautionary note. Clin.Lab Haematol. 1984;6(3):287-292. View abstract.
  • Gupta, A. K., Haberman, H. F., Pawlowski, D., Shulman, G., and Menon, I. A. Canthaxanthin. Int.J.Dermatol. 1985;24(8):528-532. View abstract.
  • Haeger-Aronsen, B., Krook, G., and Abdulla, M. Oral carotenoids for photohypersensitivity in patients with erythrohepatic protoporphyria, polymorphous light eruptions and lupus erythematodes discoides. Int.J.Dermatol. 1979;18(1):73-82. View abstract.
  • Harnois, C., Cortin, P., Samson, J., Boudreault, G., Malenfant, M., and Rousseau, A. Static perimetry in canthaxanthin maculopathy. Arch.Ophthalmol. 1988;106(1):58-60. View abstract.
  • Haxo, F. Carotenoids in the mushroom Cantharellus cinnabarinus. Botan.Gaz. 1950;112:228-232.
  • Hoffmann, J., Linseisen, J., Riedl, J., and Wolfram, G. Dietary fiber reduces the antioxidative effect of a carotenoid and alpha-tocopherol mixture on LDL oxidation ex vivo in humans. Eur.J Nutr. 1999;38(6):278-285. View abstract.
  • Isler, O. and Schudel, P. Syntheses and labeling of carotenoids. Wiss.Veroff.Deut.Ges.Ernahr. 1963;9:54-103.
  • Ito, Y., Shima, Y., Ochiai, J., Otani, M., Sasaki, R., Suzuki, S., Hamajima, N., Ogawa, H., and Aoki, K. Effects of the consumption of cigarettes, alcohol and foods on serum concentrations of carotenoids, retinol and tocopherols in healthy inhabitants living in a rural area of Hokkaido. Nihon Eiseigaku Zasshi 1991;46(4):874-882. View abstract.
  • Ito, Y., Suzuki, K., Suzuki, S., Sasaki, R., Otani, M., and Aoki, K. Serum antioxidants and subsequent mortality rates of all causes or cancer among rural Japanese inhabitants. Int.J Vitam.Nutr.Res 2002;72(4):237-250. View abstract.
  • Ito, Y., Wakai, K., Suzuki, K., Tamakoshi, A., Seki, N., Ando, M., Nishino, Y., Kondo, T., Watanabe, Y., Ozasa, K., and Ohno, Y. Serum carotenoids and mortality from lung cancer: a case-control study nested in the Japan Collaborative Cohort (JACC) study. Cancer Sci. 2003;94(1):57-63. View abstract.
  • Kanofsky, J. R. and Sima, P. D. Structural requirements for efficient cellular photoprotection by carotenoid derivatives. Photochem.Photobiol. 2004;80(3):507-517. View abstract.
  • Kanofsky, J. R. and Sima, P. D. Synthetic carotenoid derivatives prevent photosensitised killing of retinal pigment epithelial cells more effectively than lutein. Exp.Eye Res 2006;82(5):907-914. View abstract.
  • Kotake-Nara, E., Kushiro, M., Zhang, H., Sugawara, T., Miyashita, K., and Nagao, A. Carotenoids affect proliferation of human prostate cancer cells. J Nutr. 2001;131(12):3303-3306. View abstract.
  • Kubler, W. Pharmacokinetic implications of single and repeated dosage. Int.J Vitam.Nutr.Res Suppl 1989;30:25-34. View abstract.
  • Labrousse, A. L., Salmon-Ehr, V., Eschard, C., Kalis, B., Leonard, F., and Bernard, P. Recurrent painful hand crisis in a four-year-old girl, revealing an erythropoietic protoporphyria. Eur.J Dermatol 1998;8(7):515-516. View abstract.
  • Lonn, L. I. Canthaxanthin retinopathy. Arch.Ophthalmol. 1987;105(11):1590-1591. View abstract.
  • Macdonald, K., Holti, G., and Marks, J. Is there a place for beta-carotene/canthaxanthin in photochemotherapy for psoriasis? Dermatologica 1984;169(1):41-46. View abstract.
  • Mathews-Roth, M. M. Treatment of erythropoietic protoporphyria with beta-carotene. Photodermatol. 1984;1(6):318-321. View abstract.
  • Meraji, S., Ziouzenkova, O., Resch, U., Khoschsorur, A., Tatzber, F., and Esterbauer, H. Enhanced plasma level of lipid peroxidation in Iranians could be improved by antioxidants supplementation. Eur.J Clin.Nutr. 1997;51(5):318-325. View abstract.
  • Metge, P., Mandirac-Bonnefoy, C., and Bellaube, P. [Retinal thesaurismosis caused by canthaxanthin]. Bull.Mem.Soc.Fr.Ophtalmol. 1983;95:547-549. View abstract.
  • Meyer, J. C., Grundmann, H. P., Seeger, B., and Schnyder, U. W. Plasma concentrations of beta-carotene and canthaxanthin during and after stopping intake of a combined preparation. Dermatologica 1985;171(2):76-81. View abstract.
  • Muller, K., Carpenter, K. L., Challis, I. R., Skepper, J. N., and Arends, M. J. Carotenoids induce apoptosis in the T-lymphoblast cell line Jurkat E6.1. Free Radic.Res 2002;36(7):791-802. View abstract.
  • Nijman, N. M., Oosterhuis, J. A., van Bijsterveld, O. P., Baart, de la Faille, and Suurmond, D. [Canthaxanthin retinopathy]. Klin.Monatsbl.Augenheilkd. 1989;194(1):48-51. View abstract.
  • Onogi, N., Okuno, M., Matsushima-Nishiwaki, R., Fukutomi, Y., Moriwaki, H., Muto, Y., and Kojima, S. Antiproliferative effect of carotenoids on human colon cancer cells without conversion to retinoic acid. Nutr.Cancer 1998;32(1):20-24. View abstract.
  • Oosterhuis, J. A., Remky, H., Nijman, N. M., Craandijk, A., and de Wolff, F. A. [Canthaxanthin retinopathy without intake of canthaxanthin]. Klin.Monatsbl.Augenheilkd. 1989;194(2):110-116. View abstract.
  • Paetau, I., Chen, H., Goh, N. M., and White, W. S. Interactions in the postprandial appearance of beta-carotene and canthaxanthin in plasma triacylglycerol-rich lipoproteins in humans. Am.J.Clin.Nutr. 1997;66(5):1133-1143. View abstract.
  • Philipp, W. [Carotinoid deposits in the retina]. Klin.Monbl.Augenheilkd. 1985;187(5):439-440. View abstract.
  • Poh-Fitzpatrick, M. B. and Barbera, L. G. Absence of crystalline retinopathy after long-term therapy with beta-carotene. J Am Acad.Dermatol 1984;11(1):111-113. View abstract.
  • Prabhala, R. H., Maxey, V., Hicks, M. J., and Watson, R. R. Enhancement of the expression of activation markers on human peripheral blood mononuclear cells by in vitro culture with retinoids and carotenoids. J Leukoc.Biol. 1989;45(3):249-254. View abstract.
  • Raab, W. P., Tronnier, H., and Wiskemann, A. Photoprotection and skin coloring by oral carotenoids. Dermatologica 1985;171(5):371-373. View abstract.
  • Rachmilewitz, E. A., Kornberg, A., and Acker, M. Vitamin E deficiency due to increased consumption in beta-thalassemia and in Gaucher's disease. Ann.N.Y.Acad.Sci. 1982;393:336-347. View abstract.
  • Rollman, O. and Vahlquist, A. Psoriasis and vitamin A. Plasma transport and skin content of retinol, dehydroretinol and carotenoids in adult patients versus healthy controls. Arch.Dermatol Res 1985;278(1):17-24. View abstract.
  • Santamaria, L. A. and Santamaria, A. B. Cancer chemoprevention by supplemental carotenoids and synergism with retinol in mastodynia treatment. Med Oncol.Tumor Pharmacother. 1990;7(2-3):153-167. View abstract.
  • Santamaria, L. and Bianchi-Santamaria, A. Carotenoids in cancer chemoprevention and therapeutic interventions. J Nutr.Sci.Vitaminol.(Tokyo) 1992;Spec No:321-326. View abstract.
  • Santamaria, L., Benazzo, L., Benazzo, M., and Bianchi, A. First clinical case-report (1980-88) of cancer chemoprevention with beta-carotene plus canthaxanthin supplemented to patients after radical treatment. Boll.Chim.Farm. 1988;127(4):57S-61S. View abstract.
  • Segal, A., Laporte, P., Ducasse, A., and Vidal, S. [A new case of retinal thesaurismosis due to canthaxanthin]. Bull.Soc.Ophtalmol.Fr. 1985;85(1):145-147. View abstract.
  • Stich, H. F., Stich, W., Rosin, M. P., and Vallejera, M. O. Use of the micronucleus test to monitor the effect of vitamin A, beta-carotene and canthaxanthin on the buccal mucosa of betel nut/tobacco chewers. Int.J.Cancer 12-15-1984;34(6):745-750. View abstract.
  • Suhonen, R. and Plosila, M. The effect of beta-carotene in combination with canthaxanthin, Ro 8-8427 (Phenoro), in treatment of polymorphous light eruptions. Dermatologica 1981;163(2):172-176. View abstract.
  • Sujak, A., Gabrielska, J., Milanowska, J., Mazurek, P., Strzalka, K., and Gruszecki, W. I. Studies on canthaxanthin in lipid membranes. Biochim.Biophys.Acta 6-15-2005;1712(1):17-28. View abstract.
  • Teicher, V. B., Kucharski, N., Martin, H. D., van der Saag, P., Sies, H., and Stahl, W. Biological activities of Apo-canthaxanthinoic acids related to gap junctional communication. Arch.Biochem.Biophys. 5-1-1999;365(1):150-155. View abstract.
  • Thomsen, K., Schmidt, H., and Fischer, A. Beta-carotene in erythropoietic protoporphyria: 5 years' experience. Dermatologica 1979;159(1):82-86. View abstract.
  • Tronnier, H. [Protective effect of beta-carotene and canthaxanthin against UV reactions of the skin]. Z.Hautkr. 7-1-1984;59(13):859-870. View abstract.
  • Tyurin, V. A., Carta, G., Tyurina, Y. Y., Banni, S., Day, B. W., Corongiu, F. P., and Kagan, V. E. Peroxidase-catalyzed oxidation of beta-carotene in HL-60 cells and in model systems: involvement of phenoxyl radicals. Lipids 1997;32(2):131-142. View abstract.
  • Weber, U., Goerz, G., Baseler, H., and Michaelis, L. [Canthaxanthin retinopathy. Follow-up of over 6 years]. Klin.Monatsbl.Augenheilkd. 1992;201(3):174-177. View abstract.
  • White, W. S., Stacewicz-Sapuntzakis, M., Erdman, J. W., Jr., and Bowen, P. E. Pharmacokinetics of beta-carotene and canthaxanthin after ingestion of individual and combined doses by human subjects. J.Am.Coll.Nutr. 1994;13(6):665-671. View abstract.
  • Wiskemann, A. [Light protection and increase of UV tolerance]. Z.Hautkr. 11-1-1984;59(21):1454-1462. View abstract.
  • Yang, Y., Huang, C. Y., Peng, S. S., and Li, J. Carotenoid analysis of several dark-green leafy vegetables associated with a lower risk of cancers. Biomed.Environ.Sci. 1996;9(4):386-392. View abstract.
  • Yemelyanov, A. Y., Katz, N. B., and Bernstein, P. S. Ligand-binding characterization of xanthophyll carotenoids to solubilized membrane proteins derived from human retina. Exp.Eye Res 2001;72(4):381-392. View abstract.
  • Zhang, L. X., Acevedo, P., Guo, H., and Bertram, J. S. Upregulation of gap junctional communication and connexin43 gene expression by carotenoids in human dermal fibroblasts but not in human keratinocytes. Mol.Carcinog. 1995;12(1):50-58. View abstract.
  • Ziouzenkova, O., Winklhofer-Roob, B. M., Puhl, H., Roob, J. M., and Esterbauer, H. Lack of correlation between the alpha-tocopherol content of plasma and LDL, but high correlations for gamma-tocopherol and carotenoids. J Lipid Res 1996;37(9):1936-1946. View abstract.
  • Anon. A suntan in capsules - orobronze. Drug Ther Bull 1983;21:57.
  • Anon. FDA Import Alert #53-03, 1991. Availble at:
  • Anon. Permitted colouring agents for use in medicinal products - E 161 Canthaxanthine. Health and Consumer Protection - The European Commission 1998. Available at:
  • Anon. Porphyria information for patients and their families. University of Cape Town / Medical Research Council - Liver Research Center 2000. Available at:
  • Bluhm R, Branch R, Johnston P, Stein R. Aplastic anemia associated with canthaxanthin ingested for 'tanning' purposes. JAMA 1990;264:1141-2. View abstract.
  • Chang TS, Aylward W, Clarkson JG, Gass JD. Asymmetric canthaxanthin retinopathy. Am J Ophthalmol 1995;119:801-2. View abstract.
  • Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at:
  • Espaillat A, Aiello LP, Arrigg PG, et al. Canthaxanthine retinopathy. Arch Ophthalmol 1999;117:412-3.. View abstract.
  • Harnois C, Samson J, Malenfant M, Rousseau A. Canthaxanthin retinopathy. Anatomic and funtional reversibility. Arch Ophthalmol 1989;107:538-40. View abstract.
  • Herbert V. Canthaxanthin toxicity. Am J Clin Nutr 1991;53:573-4.
  • Huang DS, Odeleye OE, Watson RR. Inhibitory effects of canthaxanthin on in vitro growth of murine tumor cells. Cancer Lett 1992;65:209-13. View abstract.
  • Jackson R. Quick suntan pills in Canada. J Am Acad Dermatol 1981;4:233. View abstract.
  • Leyon H, Ros AM, Nyberg S, Algvere P. Reversibility of canthaxanthin deposits within the retina. Acta Ophthalmol (Copenh) 1990;68:607-11. View abstract.
  • Lober CW. Canthaxanthin- the "tanning" pill. J Am Acad Dermatol 1985;13:660.
  • Mathews-Roth MM. Carotenoids in erythropoietic protoporphyria and other photosensitivity diseases. Ann N Y Acad Sci, 1993; 691:127-38. View abstract.
  • Pine, D. Cool tips for a hot season. FDA/CFSAN Cosmetics 1992. Available at:
  • Rock GA, Decary F, Cole RS. Orange plasma from tanning capsules. Lancet 1981;1:1419-20.
  • Stahl W, Sies H. The role of carotenoids and retinoids in gap junctional communication. Int J Vitam Nutr Res 1998;68:354-9. View abstract.
  • Vainio H, Rautalahti M. An international evaluation of the cancer preventive potential of carotenoids. Cancer Epidemiol Biomarkers Prev 1998;7:725-8. View abstract.
  • White GL Jr, Beesley R, Thiese SM, Murdock RT. Retinal crystals and oral tanning agents. Am Fam Physician 1988;37:125-6. View abstract.

More Resources for CANTHAXANTHIN

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version. © Therapeutic Research Faculty 2009.